This HTML5 document contains 145 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n11http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34579882
rdf:type
wikibase:Item
schema:description
teaduslik artikkel vetenskaplig artikel tudományos cikk vedecký článok 2007 թուականի Յունիսին հրատարակուած գիտական յօդուած artigo científico 2007年论文 научная статья 2007年の論文 naučni članak bilimsel makale 2007年论文 ২০০৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2007年论文 mokslinis straipsnis vitskapeleg artikkel article scientifique (publié 2007) 2007 nî lūn-bûn scienca artikolo научна статия wetenschappelijk artikel artikulong pang-agham 2007年論文 2007年论文 2007年論文 wissenschaftlicher Artikel artículo científico publicado en 2007 articolo scientifico мақолаи илмӣ научни чланак מאמר מדעי vitenskapelig artikkel سائنسی مضمون article scientific مقالة علمية مقالهٔ علمی επιστημονικό άρθρο 2007年论文 article científic artículu científicu espublizáu en 2007 2007 թվականի հունիսին հրատարակված գիտական հոդված tieteellinen artikkeli vědecký článek 2007年論文 artigo científico (publicado na 2007) мақолаи илмӣ სამეცნიერო სტატია บทความทางวิทยาศาสตร์ artikull shkencor 2007年論文 научни чланак bài báo khoa học artigo científico (publicado na 2007) 2007年论文 2007年論文 videnskabelig artikel (udgivet 2007) artykuł naukowy наукова стаття, опублікована в червні 2007 2007년 논문 scientific article articol științific
p:P577
wds:Q34579882-2D632BE7-85F3-4CD4-82C8-E46A29412F12
wdt:P577
2007-06-01T00:00:00Z
p:P407
wds:Q34579882-A95D8A81-D64C-4C76-BB3C-87E18CD45C47
wdt:P407
wd:Q1860
p:P2093
wds:Q34579882-F9B219F1-8A4A-45AC-912B-8051B795C604 wds:Q34579882-F3325F14-8426-40DC-BD7D-10FBA4D7D403 wds:Q34579882-DEDDDC68-4ADE-4042-8621-534EA206A681 wds:Q34579882-D6EE7159-A547-4CBC-B6FA-0F3679486E16 wds:Q34579882-C36D910F-8CB7-4519-AF77-3A57D3967B08 wds:Q34579882-BF67C58C-9C32-429C-A819-57D4D81216D5 wds:Q34579882-7E1D84F6-0057-4E28-B41E-7C86DC90DBD5 wds:Q34579882-A255E5BE-A352-44A0-9E19-E2BA754A77BA wds:Q34579882-7A67E1CD-BF04-4384-BCA4-6B57D9F3FB3E wds:Q34579882-78B8B362-B376-40E2-986C-6CEF4D9DD16D wds:Q34579882-6D86EFB6-43A1-4332-A6F4-D1BD7EC37F58 wds:Q34579882-56972AC1-37C9-4312-938B-43BA8DDA28F1 wds:Q34579882-61AF7464-4C00-495C-BA58-9D471984D61A wds:Q34579882-36908119-13B4-4CB5-B733-F0DEAC1FFF63 wds:Q34579882-302649B5-418C-4084-AE17-B042EC6529A7 wds:Q34579882-33A626CB-20C4-4897-BB91-4C0DFE75328C wds:Q34579882-2D406326-9334-4C2B-9F05-D798EA6CD5CE wds:Q34579882-0FBCFFB6-B191-4A48-BC9C-C177D94878BE wds:Q34579882-09774780-5D76-4621-A745-9482E866A335 wds:Q34579882-06EC4C0C-44E4-48BB-B46E-638837AF56BB
wdt:P2093
Gabriela V Kornek Central European Cooperative Oncology Group Susanne Cina Arie Figer Dieter Koeberle Swiss Group for Clinical Cancer Research Werner Scheithauer Karin Tàmas Thomas Ruhstaller Jürg Bernhard Salomon M Stemmer Piercarlo Saletti Johannes Schüller Bernhard Pestalozzi György Bodoky Walter Mingrone Jean Bauer Richard Herrmann Emilio Bajetta Daniel Dietrich
rdfs:label
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
skos:prefLabel
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
schema:name
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
p:P50
wds:Q34579882-20600083-127C-4C6F-94BC-E494BFA2D4DA wds:Q34579882-064E369E-0FB7-4ADB-83FE-0BB7E8EE4574
wdt:P50
wd:Q30830855 wd:Q37068153
p:P1476
wds:Q34579882-08842678-E00F-4927-B935-FC2756376521
wdt:P1476
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
p:P304
wds:Q34579882-E3E4EB7D-41F4-4AFE-97C7-8949C97043D0
wdt:P304
2212-2217
p:P31
wds:Q34579882-0E36AFD1-CBD4-4FDB-B938-A7DCABD897E9
wdt:P31
wd:Q13442814
p:P921
wds:Q34579882-472F595D-15C7-4F9E-906F-438CBEECB583 wds:Q34579882-CC1E435F-58A2-47A0-BFDF-54DA9DA11324 wds:Q34579882-CEA06F9B-E2FF-42C5-8229-6E80848B2FB9 wds:Q34579882-F5474FFF-DEA1-4845-AD06-7C1BC8B7F0F7
wdt:P921
wd:Q42824827 wd:Q420207 wd:Q6934595 wd:Q212961
p:P698
wds:Q34579882-D86BCADD-846B-46E1-A6D6-0B59B17D9C09
wdtn:P698
n10:17538165
wdt:P698
17538165
p:P1433
wds:Q34579882-7B6215FC-73D8-486D-B58E-A14B45706255
wdt:P1433
wd:Q400292
p:P433
wds:Q34579882-0F3F712B-AA54-4C4A-8EA2-809F2BE678F0
p:P478
wds:Q34579882-7721422B-3C28-4BE8-8F50-A6F88B300C6D
wdt:P433
16
wdt:P478
25
p:P356
wds:Q34579882-66207A33-73AC-4553-BD3A-B305EFC20B5B
wdtn:P356
n11:JCO.2006.09.0886
wdt:P356
10.1200/JCO.2006.09.0886